<p>令一些股東感到惱火的是，<strong>Health Catalyst, Inc.</strong>（納斯達克代碼：HCAT）的股價在過去一個月下跌了 27%，這延續了該公司的糟糕表現。最近的下跌使得過去一年股東的損失達到了 51%。</p>
<p>由於股價大幅下跌，Health Catalyst 的市銷率（&#34;P/S&#34;）為 1 倍，這使得與美國醫療服務行業相比，它看起來像是一個買入機會，因為該行業大約一半的公司市銷率超過 2.2 倍，甚至超過 7 倍的市銷率也相當普遍。不過，僅僅根據市銷率來判斷並不明智，因為可能有原因導致其受到限制。</p>
<p>查看我們對 Health Catalyst 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893"/></p>
<p>納斯達克 GS:HCAT 市銷率與行業比較 2025 年 3 月 8 日</p>
<h3>Health Catalyst 的市銷率對股東意味着什麼？</h3>
<p>最近一段時間，Health Catalyst 的表現並不理想，因為其收入增長速度低於大多數其他公司。也許市場預計當前的收入增長乏力趨勢將持續，這使得市銷率受到壓制。如果你仍然看好這家公司，你會希望收入不會進一步惡化，並希望在它不受歡迎時能夠買入一些股票。</p>
<p>如果你想了解分析師對未來的預測，可以查看我們關於 Health Catalyst 的 <strong>免費</strong> 報告。</p>
<h2>Health Catalyst 是否有收入增長的預測？</h2>
<p>有一個內在的假設，即公司應該低於行業表現，才能使像 Health Catalyst 這樣的市銷率被認為是合理的。</p>
<p>如果我們回顧過去一年的收入增長，公司實現了 3.6% 的可觀增長。最近三年期間，收入總體增長了 27%，在一定程度上得益於其短期表現。因此，股東們可能對中期的收入增長率感到滿意。</p>
<p>展望未來，分析師預計在接下來的三年中，收入將以每年 9.8% 的速度增長。這與更廣泛行業的 11% 年增長預測相似。</p>
<p>考慮到這一點，我們發現 Health Catalyst 的市銷率落後於其行業同行，這一點頗具吸引力。顯然，一些股東對預測表示懷疑，並接受了較低的出售價格。</p>
<h2>我們可以從 Health Catalyst 的市銷率中學到什麼？</h2>
<p>Health Catalyst 最近疲軟的股價使其市銷率低於其他醫療服務公司。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
<p>我們對 Health Catalyst 的分析顯示，儘管分析師預測的收入增長與更廣泛的行業相匹配，但其市銷率仍然較低。當我們看到這樣的中等收入增長時，我們假設潛在風險是施加壓力於市銷率的原因。顯然，有些人確實在預期收入的不穩定，因為這些條件通常應該為股價提供更多支持。</p>
<p>在投資之前，還有其他重要的風險因素需要考慮，我們發現 <strong>Health Catalyst 有 2 個警告信號</strong>，你應該注意。</p>
<p>如果你對盈利能力強的公司感興趣，那麼你會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司以低市盈率交易（但已證明它們能夠增長盈利）。</p>
<p>如果你打算交易 Health Catalyst，可以在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
<p>贊助內容</p>

HCAT

<p>Health Catalyst, Inc.（納斯達克代碼：HCAT）股票在過去一個月下跌了 27%，導致過去一年損失達 51%。儘管其市銷率（P/S）僅為 1 倍，顯示出潛在價值，但收入增長卻低於行業同行。分析師預測未來三年年收入將增長 9.8%，與行業平均水平相似。然而，投資者情緒依然謹慎，這體現在低市銷率上，表明對收入穩定性的擔憂。潛在投資者在做出決策前應考慮現有風險</p>

<p>To the annoyance of some shareholders, <strong>Health Catalyst, Inc.</strong> (NASDAQ:HCAT) shares are down a considerable 27% in the last month, which continues a horrid run for the company. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 51% loss during that time.</p>
<div class="lb-trans"><p>令一些股東感到惱火的是，<strong>Health Catalyst, Inc.</strong>（納斯達克代碼：HCAT）的股價在過去一個月下跌了 27%，這延續了該公司的糟糕表現。最近的下跌使得過去一年股東的損失達到了 51%。</p>
</div><p>Since its price has dipped substantially, Health Catalyst's price-to-sales (or &#34;P/S&#34;) ratio of 1x might make it look like a buy right now compared to the Healthcare Services industry in the United States, where around half of the companies have P/S ratios above 2.2x and even P/S above 7x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's limited.</p>
<div class="lb-trans"><p>由於股價大幅下跌，Health Catalyst 的市銷率（&#34;P/S&#34;）為 1 倍，這使得與美國醫療服務行業相比，它看起來像是一個買入機會，因為該行業大約一半的公司市銷率超過 2.2 倍，甚至超過 7 倍的市銷率也相當普遍。不過，僅僅根據市銷率來判斷並不明智，因為可能有原因導致其受到限制。</p>
</div><p>View our latest analysis for Health Catalyst</p>
<div class="lb-trans"><p>查看我們對 Health Catalyst 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893" alt="" original-src="https://images.simplywall.st/asset/chart/118171469-ps-multiple-vs-industry-1-dark/1741439173893"/></p>
<p>NasdaqGS:HCAT Price to Sales Ratio vs Industry March 8th 2025</p>
<div class="lb-trans"><p>納斯達克 GS:HCAT 市銷率與行業比較 2025 年 3 月 8 日</p>
</div><h3>What Does Health Catalyst's P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>Health Catalyst 的市銷率對股東意味着什麼？</h3>
</div><p>Recent times haven't been great for Health Catalyst as its revenue has been rising slower than most other companies. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>最近一段時間，Health Catalyst 的表現並不理想，因為其收入增長速度低於大多數其他公司。也許市場預計當前的收入增長乏力趨勢將持續，這使得市銷率受到壓制。如果你仍然看好這家公司，你會希望收入不會進一步惡化，並希望在它不受歡迎時能夠買入一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Health Catalyst.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們關於 Health Catalyst 的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Health Catalyst?</h2>
<div class="lb-trans"><h2>Health Catalyst 是否有收入增長的預測？</h2>
</div><p>There's an inherent assumption that a company should underperform the industry for P/S ratios like Health Catalyst's to be considered reasonable.</p>
<div class="lb-trans"><p>有一個內在的假設，即公司應該低於行業表現，才能使像 Health Catalyst 這樣的市銷率被認為是合理的。</p>
</div><p>If we review the last year of revenue growth, the company posted a worthy increase of 3.6%. The latest three year period has also seen a 27% overall rise in revenue, aided somewhat by its short-term performance. Accordingly, shareholders would have probably been satisfied with the medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>如果我們回顧過去一年的收入增長，公司實現了 3.6% 的可觀增長。最近三年期間，收入總體增長了 27%，在一定程度上得益於其短期表現。因此，股東們可能對中期的收入增長率感到滿意。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 9.8% per annum during the coming three years according to the analysts following the company. That's shaping up to be similar to the 11% per annum growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未來，分析師預計在接下來的三年中，收入將以每年 9.8% 的速度增長。這與更廣泛行業的 11% 年增長預測相似。</p>
</div><p>With this in consideration, we find it intriguing that Health Catalyst's P/S is lagging behind its industry peers. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.</p>
<div class="lb-trans"><p>考慮到這一點，我們發現 Health Catalyst 的市銷率落後於其行業同行，這一點頗具吸引力。顯然，一些股東對預測表示懷疑，並接受了較低的出售價格。</p>
</div><h2>What We Can Learn From Health Catalyst's P/S?</h2>
<div class="lb-trans"><h2>我們可以從 Health Catalyst 的市銷率中學到什麼？</h2>
</div><p>Health Catalyst's recently weak share price has pulled its P/S back below other Healthcare Services companies. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>Health Catalyst 最近疲軟的股價使其市銷率低於其他醫療服務公司。我們認為市銷率的作用主要不是作為估值工具，而是用來衡量當前投資者情緒和未來預期。</p>
</div><p>Our examination of Health Catalyst's revealed that its P/S remains low despite analyst forecasts of revenue growth matching the wider industry. When we see middle-of-the-road revenue growth like this, we assume it must be the potential risks that are what is placing pressure on the P/S ratio. It appears some are indeed anticipating revenue instability, because these conditions should normally provide more support to the share price.</p>
<div class="lb-trans"><p>我們對 Health Catalyst 的分析顯示，儘管分析師預測的收入增長與更廣泛的行業相匹配，但其市銷率仍然較低。當我們看到這樣的中等收入增長時，我們假設潛在風險是施加壓力於市銷率的原因。顯然，有些人確實在預期收入的不穩定，因為這些條件通常應該為股價提供更多支持。</p>
</div><p>There are also other vital risk factors to consider before investing and we've discovered <strong>2 warning signs for Health Catalyst</strong> that you should be aware of.</p>
<div class="lb-trans"><p>在投資之前，還有其他重要的風險因素需要考慮，我們發現 <strong>Health Catalyst 有 2 個警告信號</strong>，你應該注意。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你對盈利能力強的公司感興趣，那麼你會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司以低市盈率交易（但已證明它們能夠增長盈利）。</p>
</div><p>If you're looking to trade Health Catalyst, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你打算交易 Health Catalyst，可以在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓你可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

在投資 Health Catalyst, Inc. (NASDAQ:HCAT) 之前要謹慎，儘管它的價格已經下降了 27%